drugset / Trial / NCT02759588
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
Timeline
- Start
- 2016-05
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
Publications
- Yu YA, Holloway RW, Mendivil AA, Ahmad S. Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer. Gynecol Oncol Rep. 2026 Jun 19;66:102145. doi: 10.1016/j.gore.2026.102145. eCollection 2026 Aug.
- Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Olvimulogene nanivacirepvec | Other / unclassified | 3e+09 unknown | Other |
| Subject | Olvimulogene nanivacirepvec | Other / unclassified | 1e+10 unknown | Other |
| Subject | Olvimulogene nanivacirepvec | Other / unclassified | 2.5e+10 unknown | Other |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | doxorubicin pegylated liposomal | Unknown | — | — |
| Background | Carboplatin | Small molecule | — | — |